INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events... READ MORE

For US healthcare professionals

REPATHA® CAN BE DOSED FROM THE COMFORT OF HOME OR ON THE GO*

One Injection. No Titration. Every 2 Weeks.1

Repatha® SureClick®

Repatha® SureClick® prefilled Autoinjector

Single-Dose Prefilled Autoinjector

  • 140 mg/mL subcutaneous injection
  • Hidden 27-gauge needle
  • Steady delivery of the 140 mg/mL dose subcutaneously up to 15 seconds
INSTRUCTIONS FOR USE
Quick Reference Guide for Injection
94%
of patients

successfully administer at home with the Repatha® SureClick® device.2,†

Supplemental injection support is available for patients who need assistance.2,‡

Up to

15
second injection

Repatha® can be injected in up to 15 seconds with the Repatha® SureClick® device. That’s just 6.5 minutes per year.§

Injection Resources

Every-2-Week Repatha® SureClick® Autoinjector 140 mg/mL

Duration: 7:27 Minutes

After receiving proper training and referring to the Instructions for Use, your Repatha® patients can reference this video for additional injection support.

Repatha Pushtronex® System**

420 mg/3.5 mL single-dose on-body infusor with prefilled cartridge system.

**The Repatha Pushtronex System has been discontinued.
Please visit https://www.repathahcp.com/pushtronexsystemupdate
for more information on how to transition your patients to a new device

Repatha® Prefilled Syringe

140 mg/mL single-dose prefilled syringe is also available.

LEARN ABOUT THE MECHANISM OF ACTION
SEE WHAT COVERAGE FOR REPATHA® LOOKS LIKE

*Repatha® should be stored in the refrigerator (35⁰F to 46⁰F) until the patient is ready to use it. The patient should wait at least 30 minutes for the autoinjector to reach room temperature before injecting. Repatha® can also be stored at room temperature (68⁰F to 77⁰F) in the original box for up to 30 days.1

†Patients who reported 2 full-dose administrations of Repatha® at weeks 2 and 4 in THOMAS-1 and weeks 4 and 8 in THOMAS-2. Patients received training from healthcare professionals on how to self-administer.

‡Amgen® nurse partners can provide patients live (over the phone) supplemental injection support at 1-844-REPATHA.

§Not inclusive of preparation and time for autoinjector to reach room temperature before injecting.

References: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Dent R, et al. SpringerPlus. 2016;5:300.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Indications

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
  • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and in adults with heterozygous familial hypercholesterolemia (HeFH)

Please see full Prescribing Information.

Important Safety Information

Back To Top